## **What is Gammagard liquid injection?**
Gammagard liquid is a form of immune globulin used for intravenous (IV) infusion in the treatment of immune-related conditions such as multifocal motor neuropathy and primary immunodeficiencies. Classified under HCPCS code J1569, it refers to the injection, immune globulin (Gammagard liquid), non-lyophilized, administered in 500 mg doses. This drug is intended for initial and additional sequential infusion as part of a primary procedure to support weakened immune systems.
The administration of immune globulin Gammagard liquid may be delivered as an initial infusion or in additional sequential infusion sessions, depending on the patient's needs. The treatment is typically performed in a clinical or outpatient setting under the supervision of a licensed healthcare provider.
Gammagard liquid plays an important role in managing chronic immune conditions, helping patients maintain function and avoid serious infections when natural antibody production is limited or absent.
## **J1569 documentation requirements**
Providers must meet specific documentation requirements for HCPCS code J1569 to receive accurate billing and reimbursement. Since Gammagard liquid is an immune globulin drug used for conditions like multifocal motor neuropathy, records should support medical necessity and show that the treatment is intended for the patient's diagnosed condition:
Key documentation includes:
- Diagnosis and indication: Document the patient's diagnosis (e.g., multifocal motor neuropathy) to justify the use of immune globulin Gammagard liquid.
- Route and method of administration: Specify that the injection of immune globulin Gammagard was administered via IV infusion as part of the primary procedure or additional sequential infusion
- Dosage and frequency: Record the exact dosage (500 mg units), number of units infused, and whether an additional hour was needed, if so, list separately
- Date and provider details: Include the administration date, licensed provider's name, and place of service
- Complete and accurate notes: Avoid errors, omissions, and other inaccuracies by ensuring detailed, compliant documentation that aligns with Medicare and Medicaid services requirements
Refer to CMS guidance and official payer pages for the latest updates. Incomplete or inaccurate documentation may result in denied claims, and neither CMS nor any governing license holder accepts responsibility for consequential damages arising from documentation errors or missing details.
## **J1569 billing requirements**
When billing for the HCPCS code J1569, providers must ensure that submitted claims reflect accurate dosage, method of administration, and whether the injection was part of an initial infusion or an additional sequential infusion. If an additional hour of infusion is provided, billers must list separately using the appropriate code to capture the full scope of services.
Medicare and Medicaid services require claims to include complete and accurate documentation that supports medical necessity. This includes referencing the date of service, dosage per 500 mg, and confirmation that Gammagard liquid was intended as part of the patient's medically necessary treatment.
Providers should routinely check CMS guidance pages and refer to local payer instructions for updates on billing formats, policies, and required supporting documentation for this immune globulin medication.
## **Other relevant codes**
- J1745 – Infliximab, 10 mg (reference product)
- J3490 – Unclassified drugs
Frequently asked questions
